AR076848A1 - Combinacion antitumoral que comprende ave8062 y sorafenib - Google Patents

Combinacion antitumoral que comprende ave8062 y sorafenib

Info

Publication number
AR076848A1
AR076848A1 ARP100101542A ARP100101542A AR076848A1 AR 076848 A1 AR076848 A1 AR 076848A1 AR P100101542 A ARP100101542 A AR P100101542A AR P100101542 A ARP100101542 A AR P100101542A AR 076848 A1 AR076848 A1 AR 076848A1
Authority
AR
Argentina
Prior art keywords
ave8062
sorafenib
combination including
combination
administered
Prior art date
Application number
ARP100101542A
Other languages
English (en)
Inventor
Brigitte Demers
Patricia Vrignaud
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR076848A1 publication Critical patent/AR076848A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a una combinacion farmacéutica antitumoral que comprende AVE8062 de formula (1) y sorafenib de formula (2), pudiendo estar estos dos agentes antitumorales en forma de base o en forma de una sal de un ácido farmacéuticamente aceptable. Reivindicacion 4: Combinacion segun la reivindicacion 1 a 3 destinada a administrarse a un paciente durante un ciclo que comprende una administracion de AVE8062 que marca el comienzo de dicho ciclo y varias administraciones de sorafenib, caracterizada por que la combinacion es escalonada en el tiempo y no concomitante, siendo administrado el AVE8062 antes de toda primera administracion de sorafenib. Reivindicacion 9: Combinacion segun una de las reivindicaciones 1 a 8 en la que se administra AVE8062 por vía parenteral y/o el sorafenib por vías oral.
ARP100101542A 2009-05-07 2010-05-06 Combinacion antitumoral que comprende ave8062 y sorafenib AR076848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
AR076848A1 true AR076848A1 (es) 2011-07-13

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101542A AR076848A1 (es) 2009-05-07 2010-05-06 Combinacion antitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
CN103140224A (zh) * 2010-06-18 2013-06-05 赛诺菲 包含奥瑞布林、紫杉烷衍生物和铂衍生物的抗肿瘤组合
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
WO2013007708A1 (en) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
US10738119B2 (en) 2014-02-18 2020-08-11 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
BR9909393A (pt) * 1998-04-03 2000-12-26 Ajinomoto Kk Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
WO2003000290A1 (fr) * 2001-06-25 2003-01-03 Ajinomoto Co., Inc. Agents antitumoraux
AU2003209118A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
SG175895A1 (en) 2011-12-29
BRPI1014197A2 (pt) 2016-04-26
EP2427185A1 (fr) 2012-03-14
CN102438608A (zh) 2012-05-02
TN2011000551A1 (fr) 2013-05-24
AU2010244254A1 (en) 2011-11-24
ECSP11011440A (es) 2011-12-30
PE20120323A1 (es) 2012-04-17
KR20120023754A (ko) 2012-03-13
WO2010128259A1 (fr) 2010-11-11
CL2011002782A1 (es) 2012-03-30
DOP2011000335A (es) 2011-12-15
IL216133A0 (en) 2012-01-31
FR2945210A1 (fr) 2010-11-12
ZA201108110B (en) 2013-01-30
US20120108641A1 (en) 2012-05-03
UY32618A (es) 2010-12-31
MA33346B1 (fr) 2012-06-01
MX2011011767A (es) 2012-02-28
TW201043225A (en) 2010-12-16
CA2761146A1 (fr) 2010-11-11
FR2945210B1 (fr) 2011-07-01
CR20110573A (es) 2011-12-08
EA201171366A1 (ru) 2012-05-30
NI201100191A (es) 2012-01-16
CO6390102A2 (es) 2012-02-29
JP2012526090A (ja) 2012-10-25

Similar Documents

Publication Publication Date Title
AR076848A1 (es) Combinacion antitumoral que comprende ave8062 y sorafenib
NZ624922A (en) Orally administered corticosteroid compositions
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
MX2013008359A (es) Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana.
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
TR201900199T4 (tr) Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler.
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
JP2013542247A5 (es)
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
RS54438B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
CA2873096A1 (en) Compositions and methods for the treatment of inflammatory bowel disease
BR112014004732A2 (pt) composto benzotiazolona
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
MX2011011716A (es) Derivados de isoquinolina novedosos.
AR083393A1 (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
PE20151282A1 (es) Combinacion de medicamentos que comprenden fenilefrina y paracetamol
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
NZ623106A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
RU2011146466A (ru) Способ послеоперационного обезболивания
RU2014152341A (ru) Композиции дезэтиламиодарона

Legal Events

Date Code Title Description
FA Abandonment or withdrawal